Kringle Pharma, Inc. (TYO:4884)
Japan · Delayed Price · Currency is JPY 500.00
-5.00 (-0.99%)
Aug 1, 2025, 3:30 PM JST
Kringle Pharma Company Description
Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines.
The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury.
Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.
Kringle Pharma, Inc.
| Country | Japan |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Kiichi Adachi |
Contact Details
Address: 207 Saito Bio Incubator Ibaraki, 567-0085 Japan | |
| Phone | 81 7 2641 8739 |
| Website | kringle-pharma.com |
Stock Details
| Ticker Symbol | 4884 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | October - September |
| Reporting Currency | JPY |
| ISIN Number | JP3270790003 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kiichi Adachi | Chief Executive Officer |